Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Bayer’s ADC for mesothelioma failed in Phase II, collaterally denting the stocks of its partners MorphoSys and ImmunoGen
- Themis has kicked off a Phase II study of its Chikungunya vaccine in Puerto Rico, where the disease is endemic
- Do presubmission meetings with the EMA open the door for drugmakers to influence MAA decisions? The EU is investigating.
- Emma Walmsley, GSK’s CEO, is making big moves to overhaul the pharma’s pipeline
Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G, Janossy Gergely, Vladimir Wrangel / shutterstock.com
Let's Continue The Conversation
Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.